The WHO has urged China to increase adoption of mRNA vaccines, given their high efficacy against variant strains.
mRNA-1345 demonstrated vaccine efficacy of 83.7% against RSV lower respiratory tract disease, defined by 2 or more symptoms in older adults
The booster vaccination trial is still ongoing and further data will provide more information around safety and efficacy.
CHMP recommendation based on safety, tolerability, and immunogenicity data from a Phase 2/3 trial of the Omicron BA.1-adapted bivalent vaccine
Complaints to be filed in both United States and Germany alleging that Pfizer and BioNTech's COVID-19 vaccine Comirnaty unlawfully infringes patents Moderna filed between 2010 and 2016
Proportion of the eligible population yet to receive a COVID-19 vaccine is comparatively small
Company is investing more than €100 million in the expansion of the Halle site
It is a two dose vaccine to be administered intramuscularly at 28 days apart
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
The study was conducted in equal laboratory conditions in the Spallanzani Institute in Italy on comparable sera samples from individuals vaccinated with Sputnik V and Pfizer with a similar level of IgG antibodies and virus-neutralizing activity (VNA) against Wuhan variant.
Subscribe To Our Newsletter & Stay Updated
